Market Overview

Synlogic Shares Positive Data From SYNB1618 Study


Synlogic (NASDAQ: SYBX) reported positive data from Phase 1/2a study of SYNB1618 in patients with Phenylketonuria.

Synlogic is a clinical-stage company applying synthetic biology to probiotic bacteria to develop novel living medicines.

Phenylketonuria is a rare genetic condition that causes an amino acid called phenylalanine to build up in the body. SYNB1618 is an oral, investigational medicine designed to metabolize phenylalanine as a treatment for phenylketonuria.

Synlogic shares closed Friday's session at $8.12. The stock has a 52-week high of $14.59 and a 52-week low of $5.75.

Related Links:

FDA Grants Fast Track Designation For Prevail's Parkinson's Treatment

Ohr Pharmaceutical Merger With Neubase Therapeutics Approved By Shareholders

Posted-In: News


Related Articles (SYBX)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Aurora Cannabis Receives Health Canada Licenses For Outdoor Cultivation

An ETF Industry Goliath Could Enter Cannabis ETF Competition